Publications by authors named "Jeff Alder"

Claim this Profile
I
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
Michael S Niederman, Jeff Alder, Matteo Bassetti, Francis Boateng, Bin Cao

Lancet Infect Dis· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
Emmanuel Weiss, Jean-Ralph Zahar, Jeff Alder, Karim Asehnoune, Matteo Bassetti

Clin Infect Dis· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
Xiaoju Lv, Jeff Alder, Li Li, William O'Riordan, Michael J Rybak

Antimicrob Agents Chemother· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
James A Karlowsky, Meredith A Hackel, Samuel K Bouchillon, Jeff Alder, Daniel F Sahm

Diagn Microbiol Infect Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Antimicrobial Agents  …  but No Susceptibility Tests!
Jane E Ambler, Kevin M Krause, Judith N Steenbergen, Nicole E Scangarella-Oman, Linda A Miller, Jeff Alder

Clin Infect Dis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.
Henry L Dorkin, Doris Staab, Elisabeth Operschall, Jeff Alder, Margarita Criollo

BMJ Open Respir Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing the need for new antibacterials--authors' reply.
John H Rex, Barry I Eisenstein, Jeff Alder, Mark Goldberger, Robert Meyer

Lancet Infect Dis· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
Robert Wilson, Tobias Welte, Eva Polverino, Anthony De Soyza, Hugh Greville, Jeff Alder

Eur Respir J· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.
John H Rex, Barry I Eisenstein, Jeff Alder, Mark Goldberger, Robert Meyer

Lancet Infect Dis· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.
Robert Wilson, Antonio Anzueto, Marc Miravitlles, Pierre Arvis, Jeff Alder

Eur Respir J· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Inge C Gyssens, Matthew Dryden, Peter Kujath, Dilip Nathwani, Nicolaas Schaper, Jeff Alder

J Antimicrob Chemother· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients.
Tahaniyat Lalani, Jerome J Federspiel, Helen W Boucher, Thomas H Rude, In-Gyu Bae, Jeff Alder

J Clin Microbiol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates.
Diane M Anastasiou, Margie Morgan, Peter J Ruane, Judith N Steenbergen, Bradley D Katz, Jeff D Alder

Diagn Microbiol Infect Dis· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
Zukile Gqada, Ben Marais, Elizabeth Wasserman, Colleen Bamford, Heidi Orth, Jeff Alder

J Clin Microbiol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Peter E Pertel, Patricia Bernardo, Charles Fogarty, Peter Matthews, Rebeca Northland, Jeff Alder

Clin Infect Dis· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
George Sakoulas, Warren Rose, Michael J Rybak, Satish Pillai, Jeff Alder

J Clin Microbiol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
Carmela T M Mascio, Jeff D Alder, Jared A Silverman

Antimicrob Agents Chemother· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
Lawrence I Mortin, Tongchuan Li, Andrew D G Van Praagh, Shuxin Zhang, Xi-Xian Zhang, Jeff D Alder

Antimicrob Agents Chemother· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Diane M Anastasiou, Grace M Thorne, Steven A Luperchio, Jeff D Alder

Int J Antimicrob Agents· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.
Lisa Friedman, Jeff D Alder, Jared A Silverman

Antimicrob Agents Chemother· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.
George Sakoulas, Jeff Alder, Claudie Thauvin-Eliopoulos, Robert C Moellering, George M Eliopoulos

Antimicrob Agents Chemother· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical relevance and correct designation of isolates nonsusceptible to daptomycin.
Jeff Alder, Barry I Eisenstein

Clin Infect Dis· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.
Jared A Silverman, Lawrence I Mortin, Andrew D G Vanpraagh, Tongchuan Li, Jeff Alder

J Infect Dis· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Judith N Steenbergen, Jeff Alder, Grace M Thorne, Francis P Tally

J Antimicrob Chemother· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.
Jeff Alder, Tongchaun Li, Donghui Yu, Larry Morton, Jared Silverman

Antimicrob Agents Chemother· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis